secwatch.observer — SEC 8-K summary
======================================

Issuer:     4D Molecular Therapeutics, Inc. (FDMT)
CIK:        0001650648
Form:       8-K
Filed at:   2024-11-13T23:59:59+00:00
Accession:  0000950170-24-126346
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

4DMT reports Q3 2024 net loss $43.8M, cash $551M; 4D-150 Phase 3 on track for Q1 2025
--------------------------------------------------------------------------------

- Net loss $43.8M (vs $10.3M Q3 2023); R&D expense $38.5M (vs $25.1M) on trial progression.
- Cash & equivalents $551M; expected to fund operations at least into H1 2027.
- Positive 4D-150 interim data: 83% injection reduction in severe population; 70-87% 52-week injection-free rate.
- 4FRONT-1 Phase 3 trial for 4D-150 in wet AMD initiation expected Q1 2025.
- New senior hires: Dhaval Desai (CDO), Christopher Simms (CCO), Carlos Quezada-Ruiz (SVP Ophthalmology).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1650648/000095017024126346/0000950170-24-126346-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1650648/000095017024126346/fdmt-20241113.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-126346

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer